Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma

Abstract

Abstract. The study of tumor biomarkers was gradually facilitated by the adoption of proteomic strategies due to less invasiveness and higher sensitivity. Colorectal cancer is one of the most commonly occurring cancers worldwide and its incidence has markedly increased in Korea. While the adoption of proteomic strategies facilitated the study of tumor biomarkers, to date, no common agreement has been derived from proteomic investigations regarding tumor markers of colorectal cancer. This study was designed to find molecules differentially expressed in colorectal cancer compared to non-tumor mucosa. Four colorectal adenocarcinoma and corresponding non-tumor tissue samples were analyzed to find previously unknown proteins via two-dimensional electrophoresis and MALDI-TOF/MS spectrometry. Western blot assays and tissue microarray (TMA) immunohistochemistry were performed to validate the identified proteins. Among the twelve up-regulated and one down-regulated proteins identified, moesin, cytokeratin (KRT) 17 and carbonic anhydrase I were validated by Western blot analysis and/or immunohistochemistry. On immunohistochemistry, both moesin and KRT17 demonstrated a tendency of increased expression as pT stage advanced. Both moesin and KRT17 were not expressed in normal colorectal epithelium. These two proteins may play a role in cancer invasion and/or metastasis in colorectal carcinoma, and could be candidate biomarkers for the diagnosis and prognosis of colorectal cancer.

Keratin17 Promotes Tumor Growth and is Associated with Poor Prognosis in Gastric Cancer

“…To date, Krt17 has been reported to be overexpressed in malignant lesions of the cervix, and plays a role in cervical tumourigenesis 22 . Similarly, Krt17 has been found in a poor prognostic phenotype of human colorectal carcinoma 18 . Previous studies reported that Krt17 was frequently expressed in the cytoplasm of tumor cells in patients with GC, and may correlate with tumor progression 23 .…”

“…In addition to its scaffolding function, the expression of Krt17 is closely related to several types of cancer, and it acts as an oncoprotein by controlling the ability of p27 (KIP1) to influence cervical cancer pathogenesis 14 . Existing literatures report Krt17 is involved in the tumourigenesis of skin tumors 15 , breast cancer 16 , esophageal squamous cell carcinoma 17 , colorectal carcinoma 18 , pancreatic ductal adenocarcinoma 19 , amongst others. However, the role of Krt17 in the development of GC is yet to be elucidated.…”

Bladder cancer detection by urinary extracellular vesicle mRNA analysis

“…On the other hand, overexpression of RAI3 in colon [ 17 ], liver [ 18 ], gastric [ 19 ] and pancreatic cancers [ 20 ] is associated with poor prognosis. KRT17 (keratin 17) has been reported to be overexpressed not only in bladder cancer [ 21 ] but also in other types of cancers such as breast [ 22 ], cervical [ 23 ], oral [ 24 ], esophagus [ 25 ], pancreatic [ 26 ] and colon cancers [ 27 ], and associated with poor prognosis of breast [ 22 ] and cervical cancers [ 23 ]. In oral cancer, KRT17 stimulates the Akt/mTOR pathway and upregulates SLC2A1 and glucose uptake which facilitates tumor growth [ 24 ].…”

Keratin 17 Promotes Lung Adenocarcinoma Progression by Enhancing Cell Proliferation and Invasion

“…The mRNA level of KRT17 was also enriched in oral squamous cell carcinoma [ 18 ]. Consistent with the RNA screening, proteomic research revealed an overexpression of KRT17 protein in malignancies [ 19 , 20 ], which was later validated by in situ transcript assay [ 21 ]. Along with more and more high-throughput discoveries on the abnormal expression of KRT17, its clinical significance was revealed in cervical squamous carcinoma [ 22 ] and gastric cancer [ 23 ].…”